Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of XJ103 in Healthy Subjects
NCT06026748Phase 1Active, not recruiting
- Sponsor
- Starmab
- Start
- Sep 2023
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pneumococcal disease comparing XJ103 Injection with Placebo (2 arms). Primary endpoint: Incidence of any adverse events. Started Sep 2023; status: active, not recruiting.
02
Drugs
XJ103
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT06026748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06026748.